Gestational hyperglycemia, characterized by elevated blood glucose levels during pregnancy, poses significant risks to fetal development, particularly in relation to neural tube defects (NTDs) and other neurological disorders. This overview synthesizes findings from literature to explore the pathophysiological mechanisms by which maternal hyperglycemia influences fetal neurodevelopment. The review focuses on studies that demonstrate how elevated maternal glucose levels lead to fetal hyperinsulinemia, oxidative stress, and impaired placental function, thereby contributing to the risk of congenital anomalies. Various methods where use to assess maternal glucose levels, fetal development, and long-term neurological outcomes, multiple findings emphasize the importance of monitoring and managing maternal blood glucose levels to mitigate risks associated with gestational hyperglycemia. Moreover, the discussion highlights the potential benefits of dietary modifications and early screening for gestational diabetes, underlining the necessity of comprehensive prenatal care, conclusions drawn from this overview stress the need for increased awareness among healthcare providers regarding the implications of gestational hyperglycemia and the implementation of effective intervention strategies to improve maternal and fetal health outcomes. By addressing the complex relationship between maternal glucose control and fetal neurological development, this overview aims to inform future research and clinical practices that prioritize the health and well-being of both mothers and their children.

Gestational hyperglycemia, characterized by elevated blood glucose levels during pregnancy, is a significant risk factor for various fetal complications, particularly affecting fetal development and neurological outcomes. Maternal hyperglycemia can disrupt the normal development of the fetus, leading to a range of congenital anomalies, including neural tube defects (NTDs), and other systemic malformations. This condition is most prevalent in women with pre-existing diabetes or gestational diabetes mellitus (GDM), which can create a hyperglycemic intrauterine environment that impairs fetal organogenesis during critical developmental windows. One of the most concerning outcomes associated with gestational hyperglycemia is the development of neural tube defects (NTDs), which are serious birth defects of the brain and spinal cord. These defects occur due to the failure of the neural tube to close properly during the early stages of embryonic development, typically within the first 28 days of gestation. Research has shown that maternal hyperglycemia increases oxidative stress and inflammatory responses, which can impair cellular processes and result in such congenital malformations.^1–3

Beyond NTDs, hyperglycemia in pregnancy has been linked to a spectrum of neurological disorders that may manifest either at birth or later in life. Infants born to hyperglycemic mothers may experience cognitive impairments, developmental delays, or even long-term issues such as epilepsy or motor dysfunctions. The precise mechanisms through which hyperglycemia induces these neurological issues are still under investigation, but emerging evidence suggests that both direct teratogenic effects of high glucose levels and secondary complications, such as placental insufficiency, may play a role.

This overview aims to explore the multifaceted impact of gestational hyperglycemia on fetal development, focusing on the relationship between maternal blood glucose levels and the occurrence of multiple birth defects, with a particular emphasis on neurological outcomes. By understanding these associations, healthcare providers can better manage at-risk pregnancies and reduce the incidence of severe fetal and neonatal complications.^4–6

This overview draws upon a range of previous studies and clinical research focused on the impact of gestational hyperglycemia on fetal development, with particular attention to neural tube defects and associated neurological disorders. A mini review of existing literature was conducted using established medical databases to identify relevant studies on this topic. Various studies focusing on tracking pregnancies affected by maternal hyperglycemia, alongside investigations into the long-term neurological outcomes in children born to mothers with elevated blood glucose levels during pregnancy. Studies employed various methods to assess the relationship between gestational hyperglycemia and fetal outcomes. These methods generally involved the measurement of maternal glucose levels through standard glucose tolerance tests and the examination of fetal development using prenatal imaging and postnatal neurological assessments. Many studies also explored maternal interventions, such as glucose control and dietary adjustments, and their effects on reducing the risk of congenital anomalies, including neural tube defects. In synthesizing the findings of these studies, this overview highlights the key trends and patterns observed across different populations and clinical settings. By examining a broad range of research, it aims to provide an integrated understanding of how gestational hyperglycemia influences fetal neurological development and what measures can be taken to mitigate these risk.^7,8

Gestational hyperglycemia disrupts the normal metabolic environment during pregnancy, leading to significant alterations in fetal development. Elevated maternal blood glucose levels cross the placenta and expose the fetus to a hyperglycemic environment, which triggers excessive insulin production in the fetus. This fetal hyperinsulinemia is associated with increased oxidative stress, which damages cells and tissues during critical periods of organogenesis. In the context of neural tube development, this oxidative stress interferes with cellular signaling and DNA repair processes, resulting in the failure of the neural tube to close properly, leading to neural tube defects (NTDs).

In addition to oxidative stress, hyperglycemia contributes to an inflammatory response that further compromises fetal development. The imbalance of glucose and insulin affects placental function, reducing the oxygen and nutrient supply to the fetus, which can impair neurodevelopment. This disrupted placental function, combined with the direct effects of high glucose on fetal neural tissues, creates a cascade of events that not only contributes to NTDs but also increases the risk of other neurological complications. This multifactorial pathophysiology illustrates the complex relationship between maternal hyperglycemia and fetal neurological outcomes, emphasizing the need for careful glucose management during pregnancy to minimize these risks.

Effect of hyperglycemia on fetal movement

Chronic hyperglycemia in a pregnant woman can lead to fetal hyperinsulinemia, where the fetus produces excessive insulin in response to high glucose levels. This can result in fetal macrosomia, which may alter fetal movement patterns. The larger size can restrict movement due to decreased space within the uterus. Hyperglycemia can lead to polyhydramnios (excessive amniotic fluid), which may affect fetal movement (Figure 1).

Figure 1 Maternal fetal glucose circulation.

Factors affect fetal movements

1. Maternal factors
1. Time of day

Many women report increased fetal activity in the evening or at night, possibly due to circadian rhythms or changes in blood sugar levels.

2. Activity level

Movement can sometimes reflect baby activity, as which as periods of maternal rest might prompt increased fetal activity.

3. Stress and emotions

Maternal stress hormones can cross the placenta and potentially influence fetal behavior

4. Diet: A surge in blood sugar

after a meal can make babies more active, while hunger might lead to reduced movement.

5. Medications

Some medications can affect fetal movements, either increasing or decreasing activity.

6. Uterine size and shape

As pregnancy progresses, the amount of space available for the fetus to move changes, potentially affecting movement patterns.

2. Fetal factors
1. Gestational age

Movement patterns change throughout pregnancy. Early movements are often subtle, becoming more pronounced and then potentially settling into a pattern as the fetus grows.

2. Sleep-wake cycles

Fetuses develop their own sleep-wake cycles, and periods of inactivity are completely normal.

3. Other factors
1. Amniotic fluid levels

Adequate amniotic fluid is essential for fetal movement as this can be reflected earthier by oligohydromonas or polyhydromans as both causes decreqsed fetal movement.

Placental health

The placenta plays a critical role in delivering oxygen and nutrients to the fetus, which affect fetal activity levels in cases such as placenta previa and abruption placenta (Figure 2).^10,11

Figure 2 Factors affect fetal movements.

Patient education

Instruct the pregnant woman to begin monitoring fetal movements daily, typically starting around 28 weeks of gestation.

Kick count method

Advise the mother to choose a time of day when the baby is usually active, often after meals. Normal: At least 10 movements within 2 hours. If fewer movements are felt, she should contact her healthcare provider.

Use of non-stress test (NST)

If decreased fetal movement is reported, a non-stress test can be performed a reactive stress test considered s having at least two fetal heart rate accelerations of

15 beats per minute (bpm) above the baseline, lasting for at least 15 seconds each, within a 20-minute period

Conducted via ultrasound if decreased movement is suspected. The BPP assesses fetal movements, muscle tone, breathing movements, and amniotic fluid levels. Each parameter is scored, with a total score of 8-10 considered normal.

Modified biophysical profile

Combines the NST and an amniotic fluid index (AFI) assessment. Useful in monitoring high-risk pregnancies where fetal movement might be reduced due to various complications.

Biophysical profile (BPP)

 Prenatal test used to assess fetal well-being, especially in high-risk pregnancies. It consists of five components, each scored on a scale of 0 to 2 points, with a maximum score of 10 points

Fetal breathing

At least one episode of rhythmic breathing lasting 30 seconds within 30 minutes. Fetal breathing movements indicate the fetus's central nervous system is functioning well, particularly the brainstem.

Fetal movements

At least three discrete body or limb movements within 30 minutes. Active fetal movement reflects good muscle tone and adequate oxygenation.

Fetal tone

 At least one episode of active extension with return to flexion of a limb or trunk, such as opening and closing of a hand. Fetal tone indicates proper neurological function and oxygenation.

Amniotic fluid volume

At least one pocket of amniotic fluid that measures at least 2 cm in vertical diameter. Adequate amniotic fluid is necessary for fetal movement and indicates proper kidney function and placental perfusion

Non-stress test (NST)

Two or more fetal heart rate accelerations of at least 15 beats per minute above the baseline, lasting at least 15 seconds, within a 20-minute period. A reactive NST suggests good oxygenation and a healthy autonomic nervous system in the fetus.

Scoring

• 8-10 points: Generally considered normal, indicating a healthy fetus.
• 6 points: Equivocal, may require further testing or monitoring.
• 4 points or less: Abnormal, usually indicating the need for immediate evaluation and possible delivery, depending on gestational age and other factors.

Guidelines

The flowchart illustrates the guidelines for managing non-stress tests (NST) and amniotic fluid volume (AFV) assessments in the context of fetal monitoring, particularly relevant for cases involving gestational hyperglycemia. A reactive NST indicates fetal well-being, while a nonreactive NST may necessitate further investigation, including real-time ultrasound. In scenarios of oligohydramnios, delivery or increased testing frequency may be required, emphasizing the importance of regular fetal monitoring. This approach is critical for identifying potential complications in pregnancies complicated by gestational hyperglycemia, which can lead to multiple defects and neurological disorders (Figure 3).

Figure 3 Guidelines for fetal monitoring.

The association between gestational hyperglycemia and the development of neural tube defects, along with other neurological disorders, underscores the critical importance of maternal health management during pregnancy. Elevated blood glucose levels create a harmful intrauterine environment that can disrupt fetal organogenesis, particularly in the early stages of development when the neural tube is forming. This review highlights the need for increased awareness and proactive measures to monitor and control maternal glucose levels, especially in populations at risk for gestational diabetes. Furthermore, findings from previous studies emphasize the potential benefits of dietary modifications and proper prenatal care in reducing the incidence of congenital anomalies. As healthcare providers work towards optimizing maternal and fetal outcomes, understanding the pathophysiological mechanisms behind gestational hyperglycemia can inform effective intervention strategies and ultimately improve the long-term health of both mothers and their children.^11–13

In conclusion, gestational hyperglycemia poses significant risks to fetal development, particularly regarding the formation of neural tube defects and other neurological disorders. The evidence reviewed underscores the importance of maintaining optimal maternal glucose levels throughout pregnancy to mitigate these risks. By recognizing the pathophysiological mechanisms involved, including oxidative stress and impaired placental function, healthcare providers can implement targeted interventions that focus on both prevention and management strategies. Additionally, this overview highlights the necessity of routine screening for gestational diabetes and educational efforts directed at expectant mothers regarding the implications of hyperglycemia. Early detection and effective management can not only improve pregnancy outcomes but also enhance the long-term health of offspring. As research continues to evolve, further investigations into the relationship between maternal hyperglycemia and fetal neurological outcomes will be crucial in shaping guidelines and policies aimed at safe guarding maternal and child health.

None.

None to declare.

The author declares that there is no conflicts of interest.

1. D'Souza SW, Copp AJ, Greene ND, et al. Maternal inositol status and neural tube defects: a role for the human yolk sac in embryonic inositol delivery? Advances in Nutrition. 2021;12(1):212–222.
2. Vena F, D’Ambrosio V, Paladini V, et al. Risk of neural tube defects according to maternal body mass index: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2021;35(25):7296–7305.
3. Rodolaki K, Pergialiotis V, Iakovidou N, et al. The impact of maternal diabetes on the future health and neurodevelopment of the offspring: a review of the evidence. Front Endocrinol (Lausanne). 2023;14:1125628.
4. Papazoglou AS, Moysidis DV, Panagopoulos P, et al. Maternal diabetes mellitus and its impact on the risk of delivering a child with congenital heart disease: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2021;35(25):7685–7694.
5. Chen KR, Yu T, Lien YJ, et al. Childhood neurodevelopmental disorders and maternal diabetes: A population-based cohort study. Dev Med Child Neurol. 2023;65(7):933–941.
6. Abodeely A, Roye D, Harrington DT, et al. Pregnancy outcomes after bariatric surgery: maternal, fetal, and infant implications. Surg Obes Relat Dis. 2008;4(3):464–471.
7. Chez RA. Effects of maternal hyperglycemia on fetal development. Diabetes Care. 1980;3(3):435–436.
8. Perna R, Loughan AR, Le J, et al. Gestational diabetes: long-term central nervous system developmental and cognitive sequelae. Appl Neuropsychol Child. 2014;4(3):217–220.
9. Rasmussen SA, Chu SY, Kim SY, et al. Maternal obesity and risk of neural tube defects: a metaanalysis. Am J Obstet Gynecol. 2008;198(6):611–619.
10. Ye W, Luo C, Huang J, et al. Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis. BMJ. 2022;377.
11. McIntyre HD, Catalano P, Zhang C, et al. Gestational diabetes mellitus. Nat Rev Dis Primers. 2019;5(1):47.
12. Guo D, Ju R, Dai J, et al. Autism spectrum disorders in offspring exposed to maternal gestational diabetes: a meta-analysis and systematic review. Rev J Autism Dev Disord. 2023.
13. Zhang L, Zhang Y, Li Z, et al. Maternal periconceptional body mass index and risk for neural tube defects: results from a large cohort study in China. J Matern Fetal Neonatal Med. 2019;34(2):274–280.